Source: PR Newswire

Press Release: Leap Therapeutics : Leap Therapeutics to Present Updated Data for DKN-01 Monotherapy and Paclitaxel Combination at the 2019 International Gynecologic Cancer Society Annual Global Meeting

CAMBRIDGE, Mass., Sept. 17, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX) today announced an oral and poster presentation of updated clinical data from its ongoing Phase 2 clinical trial of DKN-01, its anti-Dickkopf-1 (DKK1) antibody, as both a monotherapy and in combination...

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Chris Mirabelli's photo - CEO of Leap Therapeutics


Chris Mirabelli

CEO Approval Rating


Leap Therapeutics researches, develops and commercializes monoclonal antibodies that enable immune system to identify and attack cancer cells. Read more